This HTML5 document contains 111 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://linked.opendata.cz/resource/drugbank/drug/DB00547/identifier/wikipedia/
n15http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00547/identifier/pharmgkb/
n7http://linked.opendata.cz/resource/AHFS/
n27http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00547/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/drugbank/mixture/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00547/identifier/pubchem-substance/
n21http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00547/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00547/identifier/national-drug-code-directory/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n28http://www.drugs.com/cdi/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00547/identifier/chemspider/
n5http://linked.opendata.cz/resource/drugbank/property/
n13http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00547/identifier/chebi/
n8http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00547
rdf:type
n3:Drug
n3:description
A topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc. [PubChem]
n3:dosage
n26:271B4421-363D-11E5-9242-09173F13E4C5 n26:271B4422-363D-11E5-9242-09173F13E4C5 n26:271B4423-363D-11E5-9242-09173F13E4C5 n26:271B4424-363D-11E5-9242-09173F13E4C5 n26:271B4425-363D-11E5-9242-09173F13E4C5 n26:271B4426-363D-11E5-9242-09173F13E4C5 n26:271B4427-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
n3:indication
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
n3:manufacturer
n27:271B440D-363D-11E5-9242-09173F13E4C5 n27:271B440B-363D-11E5-9242-09173F13E4C5 n27:271B440C-363D-11E5-9242-09173F13E4C5 n27:271B4409-363D-11E5-9242-09173F13E4C5 n27:271B440A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00547 n21:DB00547
dcterms:title
Desoximetasone
adms:identifier
n10:PA164746011 n11:Desoximetasone n18:51672-1271-1 n19:DB00547 n20:691037 n22:4470604 n23:5311067 n24:46506793
n3:mechanismOfAction
The precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A<sub>2</sub> inhibitory proteins, collectively called lipocortins. This is achieved first by the drug binding to the glucocorticoid receptors which then translocates into the nucleus and binds to DNA causing various activations and repressions of genes. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A<sub>2</sub>.
n3:packager
n27:271B4403-363D-11E5-9242-09173F13E4C5 n27:271B4404-363D-11E5-9242-09173F13E4C5 n27:271B4401-363D-11E5-9242-09173F13E4C5 n27:271B4402-363D-11E5-9242-09173F13E4C5 n27:271B4407-363D-11E5-9242-09173F13E4C5 n27:271B4408-363D-11E5-9242-09173F13E4C5 n27:271B4405-363D-11E5-9242-09173F13E4C5 n27:271B4406-363D-11E5-9242-09173F13E4C5 n27:271B43FF-363D-11E5-9242-09173F13E4C5 n27:271B4400-363D-11E5-9242-09173F13E4C5 n27:271B43FD-363D-11E5-9242-09173F13E4C5 n27:271B43FE-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Corticosteroids are bound to plasma proteins in varying degrees, are metabolized primarily in the liver and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.Pharmacokinetic studies in men with Desoximetasone Cream USP, 0.25% with tagged desoximetasone showed a total of 5.2% ± 2.9% excretion in urine (4.1% ± 2.3%) and feces (1.1% ± 0.6%)
n3:synonym
Desoximetason (11beta,16alpha)-9-Fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione Desoximetasonum Désoximétasone Desoximetasona 9alpha-Fluoro-16alpha-methyl-delta(1)-corticosterone Desoxymethasone
n3:toxicity
Topically applied desoximetasone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).
n6:hasAHFSCode
n7:84-06-00
n3:mixture
n14:271B43FB-363D-11E5-9242-09173F13E4C5 n14:271B43FC-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Bound to plasma proteins in varying degrees.
n3:synthesisReference
Kieslich, K., Kerb, U. and Raspe, G.; U S . Patent 3,232,839; February 1,1966; assigned to Schering AG, Germany.
foaf:page
n13:top1452.shtml n15:desoximeta.htm n28:desoximetasone-cream.html
n3:IUPAC-Name
n5:271B442C-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4432-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4431-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B442E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B442F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4430-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B442A-363D-11E5-9242-09173F13E4C5 n5:271B4442-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B442B-363D-11E5-9242-09173F13E4C5 n5:271B4428-363D-11E5-9242-09173F13E4C5 n5:271B4444-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B4429-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n8:D07XC02 n8:D07AC03
n3:H-Bond-Acceptor-Count
n5:271B4438-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4439-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4433-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4434-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4436-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4435-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4437-363D-11E5-9242-09173F13E4C5
n3:absorption
Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
382-67-2
n3:containedIn
n4:271B441A-363D-11E5-9242-09173F13E4C5 n4:271B441B-363D-11E5-9242-09173F13E4C5 n4:271B4418-363D-11E5-9242-09173F13E4C5 n4:271B4419-363D-11E5-9242-09173F13E4C5 n4:271B4420-363D-11E5-9242-09173F13E4C5 n4:271B441C-363D-11E5-9242-09173F13E4C5 n4:271B441D-363D-11E5-9242-09173F13E4C5 n4:271B441F-363D-11E5-9242-09173F13E4C5 n4:271B441E-363D-11E5-9242-09173F13E4C5 n4:271B440F-363D-11E5-9242-09173F13E4C5 n4:271B4410-363D-11E5-9242-09173F13E4C5 n4:271B440E-363D-11E5-9242-09173F13E4C5 n4:271B4412-363D-11E5-9242-09173F13E4C5 n4:271B4413-363D-11E5-9242-09173F13E4C5 n4:271B4411-363D-11E5-9242-09173F13E4C5 n4:271B4416-363D-11E5-9242-09173F13E4C5 n4:271B4417-363D-11E5-9242-09173F13E4C5 n4:271B4414-363D-11E5-9242-09173F13E4C5 n4:271B4415-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B443E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4440-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4441-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B4443-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B443D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B443C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B443F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B442D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B443A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B443B-363D-11E5-9242-09173F13E4C5